EPS for HMS Holdings Corp. (HMSY) Expected At $0.18; 3 Analysts Are Bullish Pluristem Therapeutics Inc. (PSTI) Last Week

February 15, 2018 - By Linda Rogers

Among 3 analysts covering Pluristem Therapeutics (NASDAQ:PSTI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pluristem Therapeutics had 12 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Tuesday, December 22. The rating was maintained by H.C. Wainwright on Tuesday, January 16 with “Buy”. The stock of Pluristem Therapeutics Inc. (NASDAQ:PSTI) has “Hold” rating given on Monday, February 13 by Maxim Group. The rating was maintained by Maxim Group on Wednesday, August 16 with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Thursday, August 17. Maxim Group upgraded Pluristem Therapeutics Inc. (NASDAQ:PSTI) on Monday, June 19 to “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, September 6. The rating was maintained by Maxim Group on Tuesday, August 18 with “Buy”. The firm earned “Buy” rating on Tuesday, July 19 by H.C. Wainwright. The stock of Pluristem Therapeutics Inc. (NASDAQ:PSTI) has “Buy” rating given on Friday, August 14 by MLV. See Pluristem Therapeutics Inc. (NASDAQ:PSTI) latest ratings:

16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
06/10/2017 Broker: Seaport Global Rating: Buy New Target: $5 Initiates Coverage On
06/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
17/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
16/08/2017 Broker: Maxim Group Rating: Buy New Target: $2.0 Maintain

Analysts expect HMS Holdings Corp. (NASDAQ:HMSY) to report $0.18 EPS on February, 23.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.18 EPS. HMSY’s profit would be $15.14M giving it 21.31 P/E if the $0.18 EPS is correct. After having $0.13 EPS previously, HMS Holdings Corp.’s analysts see 38.46% EPS growth. The stock increased 1.86% or $0.28 during the last trading session, reaching $15.34. About 588,042 shares traded. HMS Holdings Corp. (NASDAQ:HMSY) has risen 13.44% since February 15, 2017 and is uptrending. It has underperformed by 3.26% the S&P500.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $149.73 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

Investors sentiment increased to 2.5 in Q3 2017. Its up 1.30, from 1.2 in 2017Q2. It increased, as 5 investors sold Pluristem Therapeutics Inc. shares while 1 reduced holdings. 6 funds opened positions while 9 raised stakes. 3.73 million shares or 11.20% more from 3.36 million shares in 2017Q2 were reported. 181,700 were reported by California Pub Employees Retirement System. Tower Rech Cap Ltd Llc (Trc) holds 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI) or 80 shares. 1.58 million were reported by Renaissance Techs Limited Liability Corporation. 71,200 are held by Hightower Advsrs Ltd Co. Focused Wealth Mgmt Inc has 0.01% invested in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Van Eck Associate reported 0% stake. 1,000 are held by Wells Fargo And Mn. Geode Cap Mgmt Ltd Liability Corporation holds 0% or 41,630 shares. Psagot House Limited reported 129,522 shares. Commonwealth Equity Inc holds 0% or 29,516 shares. Millennium Management Lc has 28,297 shares. Bankshares Of America De reported 128 shares stake. Moreover, Heritage has 0.01% invested in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 74,878 shares. Citadel Advisors Lc holds 27,700 shares. Riggs Asset Managment Communication holds 1,543 shares.

The stock increased 1.49% or $0.02 during the last trading session, reaching $1.36. About 130,259 shares traded. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 7.80% since February 15, 2017 and is downtrending. It has underperformed by 24.50% the S&P500.

Among 10 analysts covering HMS Holdings (NASDAQ:HMSY), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. HMS Holdings had 25 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was initiated by Credit Suisse on Wednesday, June 1 with “Outperform”. Robert W. Baird maintained HMS Holdings Corp. (NASDAQ:HMSY) rating on Monday, October 2. Robert W. Baird has “Buy” rating and $22.0 target. The rating was downgraded by Bank of America to “Neutral” on Tuesday, July 21. The rating was maintained by Robert W. Baird on Friday, November 10 with “Buy”. The firm earned “Hold” rating on Thursday, August 18 by Jefferies. Robert W. Baird maintained it with “Buy” rating and $18.0 target in Friday, November 17 report. The firm earned “Hold” rating on Friday, June 16 by Jefferies. The rating was upgraded by Zacks on Monday, September 21 to “Hold”. As per Sunday, October 29, the company rating was maintained by Canaccord Genuity. The firm has “Strong Buy” rating given on Thursday, August 10 by Raymond James.

HMS Holdings Corp., through its subsidiaries, operates in the healthcare insurance benefit cost containment market in the United States. The company has market cap of $1.29 billion. It provides coordination of benefits services to government and commercial healthcare payers and sponsors to coordinate benefits for claims; and payment integrity services that ensure healthcare claims billed are accurate and appropriate, as well as care management and member analytics technologies. It has a 56.4 P/E ratio. The company's services also enable clients to recover improper payments; prevent future improper payments; reduce fraud, waste, and abuse; and ensure regulatory compliance.

Since August 24, 2017, it had 0 buys, and 3 selling transactions for $1.37 million activity. On Thursday, August 24 the insider Neuman Semone sold $366,543. 29,894 shares were sold by LUCIA WILLIAM C, worth $597,880. Another trade for 22,907 shares valued at $404,004 was made by Nustad Cynthia on Thursday, August 31.

Investors sentiment increased to 1.26 in 2017 Q3. Its up 0.27, from 0.99 in 2017Q2. It improved, as 23 investors sold HMS Holdings Corp. shares while 51 reduced holdings. 29 funds opened positions while 64 raised stakes. 78.86 million shares or 2.08% more from 77.25 million shares in 2017Q2 were reported. Schwab Charles invested in 506,655 shares or 0.01% of the stock. Wellington Mngmt Group Llp holds 0.01% of its portfolio in HMS Holdings Corp. (NASDAQ:HMSY) for 2.82M shares. Comerica Fincl Bank reported 0.02% stake. Canada Pension Plan Inv Board has invested 0.01% in HMS Holdings Corp. (NASDAQ:HMSY). Federated Investors Pa has invested 0% in HMS Holdings Corp. (NASDAQ:HMSY). The Quebec – Canada-based Public Sector Pension Inv Board has invested 0% in HMS Holdings Corp. (NASDAQ:HMSY). Fdx Advsrs Inc invested 0.01% in HMS Holdings Corp. (NASDAQ:HMSY). Eagle Asset Mngmt reported 0.36% in HMS Holdings Corp. (NASDAQ:HMSY). Cornerstone Mngmt Holding Ltd Co reported 0% stake. Price T Rowe Assocs Md stated it has 5.09M shares. Jupiter Asset Mgmt accumulated 240,392 shares. Louisiana State Employees Retirement Systems, Louisiana-based fund reported 34,100 shares. Bank & Trust Of Nova Scotia holds 71,273 shares. Etrade Capital Management Llc invested in 65,406 shares or 0.05% of the stock. Wells Fargo Mn invested 0% of its portfolio in HMS Holdings Corp. (NASDAQ:HMSY).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: